[go: up one dir, main page]

GT201500035A - Composición farmacéutica oral en forma de microesferas y proceso de elaboración - Google Patents

Composición farmacéutica oral en forma de microesferas y proceso de elaboración

Info

Publication number
GT201500035A
GT201500035A GT201500035A GT201500035A GT201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A GT 201500035 A GT201500035 A GT 201500035A
Authority
GT
Guatemala
Prior art keywords
microspheres
pharmaceutical composition
oral pharmaceutical
elaboration process
composition
Prior art date
Application number
GT201500035A
Other languages
English (en)
Inventor
Barranco Hernandez Gustavo
Del Coral Luna Guiza María
Senosiain Arroyo Héctor
Original Assignee
Laboratorios Senosiain S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201500035(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain S A De C V filed Critical Laboratorios Senosiain S A De C V
Publication of GT201500035A publication Critical patent/GT201500035A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN PARA ADMINISTRACIÓN ORAL EN FORMA DE MICROPARTÍCULAS, POR EJEMPLO MICROESFERAS O PELLETS, ASÍ COMO EL PROCESO PARA SU ELABORACIÓN. LA INVENCIÓN TAMBIÉN SE REFIERE A UNA COMPOSICIÓN QUE CONTIENE UN DIURÉTICO Y EL USO DE LA COMPOSICIÓN PARA EL TRATAMIENTO DE EDEMA, TRASTORNOS CARDIOVACULARES, HIPERTENSIÓN, DAÑO RENAL, DAÑO HEPÁTICO, ENTRE OTROS.
GT201500035A 2012-08-17 2015-02-16 Composición farmacéutica oral en forma de microesferas y proceso de elaboración GT201500035A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012009583A MX351059B (es) 2012-08-17 2012-08-17 Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.

Publications (1)

Publication Number Publication Date
GT201500035A true GT201500035A (es) 2017-10-24

Family

ID=50435594

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500035A GT201500035A (es) 2012-08-17 2015-02-16 Composición farmacéutica oral en forma de microesferas y proceso de elaboración

Country Status (8)

Country Link
CL (1) CL2015000375A1 (es)
CO (1) CO7310526A2 (es)
CR (1) CR20150077A (es)
DO (1) DOP2015000028A (es)
GT (1) GT201500035A (es)
MX (1) MX351059B (es)
PE (1) PE20150710A1 (es)
WO (1) WO2014027334A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685269T3 (es) 2013-03-27 2018-10-08 F. Hoffmann-La Roche Ag Marcadores genéticos para predecir el grado de respuesta al tratamiento
CA2953483C (en) 2014-07-30 2023-04-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
CN104523710B (zh) * 2014-12-30 2018-05-25 石药集团欧意药业有限公司 一种硫酸氢氯吡格雷阿司匹林复合双层片及其制备方法
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3582777A4 (en) 2017-02-17 2020-12-23 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITION OF APIXABAN
CN106821996A (zh) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 马来酸依那普利颗粒剂及其制备方法
ES2988919T3 (es) * 2018-04-16 2024-11-22 Bristol Myers Squibb Co Formulaciones de apixaban
KR102045721B1 (ko) * 2019-03-27 2019-11-18 주식회사 씨트리 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구
WO2021168043A1 (en) * 2020-02-19 2021-08-26 Nano Pharmasolutions, Inc. Therapeutic agent nanoparticles and methods of preparation
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN113413364A (zh) * 2021-05-31 2021-09-21 辰欣药业股份有限公司 一种依诺肝素钠注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226990A1 (en) * 2006-01-27 2010-09-09 The Provost, Fellows And Scholars Of The College O Method of Producing Porous Microparticles
MXPA06010972A (es) * 2006-09-25 2009-04-17 World Trade Imp Export Wtie Ag Proceso para estabilizacion de famotidina.
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.

Also Published As

Publication number Publication date
MX351059B (es) 2017-09-29
CL2015000375A1 (es) 2015-07-10
CO7310526A2 (es) 2015-06-30
DOP2015000028A (es) 2015-03-15
PE20150710A1 (es) 2015-05-28
WO2014027334A3 (es) 2014-04-10
CR20150077A (es) 2015-05-13
MX2012009583A (es) 2014-02-26
WO2014027334A2 (es) 2014-02-20

Similar Documents

Publication Publication Date Title
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CR20150326A (es) Inhibidores de autotaxina
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
CL2013002650A1 (es) Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros.
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?